Board Meeting Details

The Board of Directors meeting was held on Saturday, November 14, 2026, at the Corporate Office situated at 63, Industrial Area, Phase-2, Panchkula, Haryana. The meeting commenced at 12:00 Noon and concluded at 03:28 P.M.

Key Approvals

1. Approval of Unaudited Standalone Financial Results for Half-Year Ended September 30, 2026

  • Board reviewed and approved the unaudited standalone financial results prepared in accordance with Indian Accounting Standards (Ind AS)
  • Results were reviewed and recommended by the Audit Committee
  • Company voluntarily adopted Ind AS with effect from April 01, 2026
  • Limited Review Report issued by Statutory Auditors (M/s. Avnish Sharma & Associates) attached

2. Approval of Unaudited Consolidated Financial Results for Half-Year Ended September 30, 2026

  • Board reviewed and approved the unaudited consolidated financial results prepared in accordance with Ind AS
  • Results were reviewed and recommended by the Audit Committee
  • Company voluntarily adopted Ind AS with effect from April 01, 2026
  • Limited Review Report issued by Statutory Auditors attached

3. Approval of Proposed Related Party Transactions

  • Approved business transactions with Longevity Science Private Limited for aggregate value not exceeding ₹12,00,00,000 (₹12 crore) during FY 2026-27
  • Transactions subject to commercial terms mutually agreed between parties
  • Compliance with Companies Act, 2013 (Sections 177 and 188) and SEBI LODR Regulation 23
  • Company proposes to subscribe to 51% share capital of Longevity Science Private Limited, making it a subsidiary subject to completion of formalities

Financial Results Highlights (Standalone)

Income Statement (₹ in lakhs):

  • Revenue from Operations: 9,586.22 (H1 FY27) vs 6,629.14 (H1 FY26)
  • Other Income: 34.81 (H1 FY27) vs 9.97 (H1 FY26)
  • Total Income: 9,621.03 (H1 FY27) vs 6,639.11 (H1 FY26)
  • Profit before tax: 716.49 (H1 FY27) vs 149.87 (H1 FY26)
  • Exceptional Items: 46.16 (related to fire incident)
  • Profit after tax: 475.98 (H1 FY27) vs 190.40 (H1 FY26)
  • Basic EPS: ₹4.53 (H1 FY27) vs ₹1.97 (H1 FY26)

Balance Sheet (₹ in lakhs as at September 30, 2026):

  • Total Assets: 18,130.27
  • Total Equity: 7,212.25
  • Total Liabilities: 10,918.02
  • Share Capital: 1,051.10
  • Other Equity: 6,161.15

Key Notes to Financial Statements

1. First-time Ind AS Adoption: Company voluntarily adopted Ind AS from April 1, 2026, with transition date of April 1, 2025

2. Fire Incident: Major fire occurred at factory premises on April 27, 2026, causing substantial damage to building, plant, machinery, inventories and other assets. Insurance claim of ₹5,49,93,185 disclosed as receivable pending final assessment. Uninsured portion of inventory loss recognized as exceptional item of ₹46.16 lakhs.

3. GST Reconciliation: Company reversed Input Tax Credit of ₹84,49,225 for inventories destroyed in fire. Reconciliation process for mismatches is ongoing.

4. Associate Company: Consolidated results include unaudited results of associate Damaira Pharmaceuticals Private Limited with total assets of ₹8,855.88 lakhs and revenue of ₹2,369.18 lakhs for H1 FY27.

5. Subsidiary: Wholly-owned foreign subsidiary Astonea LLC in Wyoming, USA exists but no business operations yet commenced.

6. Future Event: On October 8, 2026, company proposed to subscribe to 51% share capital of Longevity Science Private Limited, constituting a non-adjusting event after reporting period.

Management Discussion & Analysis

Financial Performance (Consolidated, ₹ crore):

  • Revenue: ₹95.86 Cr (H1 FY27) vs ₹66.29 Cr (H1 FY26) - +44.6% YoY
  • EBITDA: ₹13.20 Cr (H1 FY27) vs ₹5.48 Cr (H1 FY26) - +140.7% YoY
  • EBITDA Margin: 13.8% (H1 FY27) vs 8.3% (H1 FY26) - +550 bps
  • PAT: ₹4.82 Cr (H1 FY27) vs ₹1.90 Cr (H1 FY26) - +153.3% YoY
  • PAT Margin: 5.0% (H1 FY27) vs 2.9% (H1 FY26) - +216 bps

Balance Sheet Metrics:

  • Gross Borrowings: ₹57.15 crore (Sep 2026) vs ₹43.00 crore (Mar 2026)
  • Net Worth: ₹72.19 crore (Sep 2026) vs ₹67.30 crore (Mar 2026)
  • Debt to Equity: 0.79x (Sep 2026) vs 0.64x (Mar 2026)
  • Debt to EBITDA (LTM): 2.6x (Sep 2026) vs 3.1x (Mar 2026)

Business Update:

  • OTC portfolio growing ~5% month-on-month
  • Young Fuel anti-ageing cream launched in H1 with good start
  • Tablet output capacity increased by 35%
  • Plant compliant with revised Schedule M and WHO-GMP
  • Export distributors appointed in Guatemala and Panama, covering 9 markets
  • 95 dossiers filed in Nicaragua, Bolivia, Guatemala and Panama
  • Plant inspections completed in Ghana, expected in Ethiopia and Kenya

Guidance:

  • FY27 Revenue target: ₹215 crore or more
  • FY27 EBITDA Margin: 13-15%
  • FY27 PAT Margin: 5-6%
  • FY28 Revenue target: ₹300 crore or more
  • FY29 Revenue target: ₹405 crore or more (~40% CAGR from FY26)
  • Expecting ~60 product registrations in exports in Q1 FY28